Search

The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge oncology research. ASCO 2021 will focus on Equity: Every Patient. Every Day. Everywhere.

… Wednesday, June 2, 2021 Thousands of oncology experts from around the world will tune in from June 4 to June 8 for the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting . The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and

Learn how tiny sensors made of nanotubes could serve as implantable devices that offer a noninvasive way to monitor cancer and its treatments.

… Tuesday, March 14, 2017 Summary It is difficult to monitor diseases like cancer without repeated biopsies and imaging scans. A solution could be offered by the field of nanotechnology , in the form of tiny sensors made up of carbon nanotubes. The sensors could be implanted under the skin, and a small

Dr. Bob Li will present registrational phase II data from the first-ever trial of a drug that blocks cancer gene KRAS.

… Friday, January 29, 2021 International scientists, researchers, physicians and patient advocates in the field of lung cancer and thoracic malignancies will tune in January 28-31, 2021, for the 2020 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer

Learning more about epithelioid hemangioendothelioma (EHE) is an ongoing mission of MSK’s sarcoma research.

… Wednesday, July 21, 2021 Memorial Sloan Kettering has been a leader in the care of sarcoma patients for decades, treating about 70% of the cases in the New York City tri-state area. A disease largely affecting young people, sarcoma is a rare cancer of the bones and soft tissues with more than 50 subtypes

Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (COTELLIC®) for the treatment of adult patients with the family of blood diseases know as histiocytic neoplasms (HN). These diseases include: Erdheim-Chester Disease, Rosai-Dorfman, and Langerhans Histiocytosis. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma.

… Tuesday, November 1, 2022 Memorial Sloan Kettering Cancer Center (MSK) announced today that the U.S. Food and Drug Administration (FDA) has approved the oral MEK inhibitor drug cobimetinib (Cotellic ® ) for the treatment of adult patients with the family of blood diseases known as histiocytic neoplasms

Learn how high-intensity focused ultrasound (HIFU) can help some men with prostate cancer avoid surgery or radiation.

… Monday, June 30, 2025 For people with  prostate cancer  considered “intermediate risk” —  small tumors confined to one area of the prostate – doctors are increasingly using a treatment known as  focal therapy  (partial gland ablation). One approach uses an advanced and highly precise energy source known

This article is Part 3 of our three-part series summarizing how MSK’s biological insights and expertise fuel innovative treatment approaches for patients with rare head and neck cancers.

… Friday, March 22, 2024 This article is Part 3 of our three-part series summarizing how MSK’s biological insights and expertise fuel innovative treatment approaches for patients with rare head and neck cancers. In Part 3 below, we  summarize MSK-led advances in non-melanoma skin of the head and neck and

Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center have identified the molecular basis of this increasingly prevalent complication of cancer. With the help of a mouse model, researchers have identified a drug strategy that may combat this virtually untreatable condition. This research by Joan Massagué, PhD, Adrienne Boire, MD, PhD, and colleagues, was published in the March 9, 2017 issue of Cell. For more information on this work and to speak with the study authors, contact [email protected].

… Thursday, March 9, 2017 Bottom Line: Leptomeningeal metastasis, cancer that has spread to the areas surrounding the brain and spinal cord, has long been a formidable clinical challenge for oncologists. Researchers at Memorial Sloan Kettering Cancer Center (MSK) have identified the molecular basis of

In the future, more-advanced genetic testing might offer better ways to match up patients who need a bone marrow transplant with potential donors.

… Tuesday, September 4, 2012 Summary In the future, more-advanced genetic testing might offer better ways to match up patients who need a bone marrow transplant with potential donors. A recent study by Memorial Sloan Kettering researchers is a step in the direction of improving strategies to find matching

An international study led by MSK investigators has found that liquid biopsies may improve survival in people with lung cancer. These blood tests are easier for patients than more traditional tissue biopsies.

… Thursday, November 10, 2022 An international study led by MSK investigators has found that liquid biopsies may improve survival in people with lung cancer. These blood tests are easier for patients than more traditional tissue biopsies. Moments after getting bad news about her lung cancer , Joyce Tyson